Home / Health / PCOS Patients Flock to Weight-Loss Drugs
PCOS Patients Flock to Weight-Loss Drugs
9 Dec
Summary
- PCOS prescriptions for GLP-1 drugs surged sevenfold since 2021.
- Women with PCOS increasingly use weight-loss drugs for symptom management.
- Lack of targeted PCOS trials by drugmakers is a missed women's health opportunity.
Women diagnosed with Polycystic Ovary Syndrome (PCOS) are increasingly seeking GLP-1 weight-loss drugs to manage their hormonal disorder's symptoms. Prescriptions for these medications among women with PCOS have risen more than sevenfold since 2021, indicating a significant shift in treatment approaches.
Despite the observed symptom improvements, pharmaceutical companies Eli Lilly and Novo Nordisk have not launched specific clinical trials for PCOS. This absence of dedicated research is viewed by medical professionals as a missed opportunity to advance women's health and better understand the condition, particularly in patients who are not overweight.
While the exact mechanisms are still under investigation, early studies and anecdotal evidence suggest that GLP-1 drugs may alleviate PCOS symptoms by reducing weight and improving insulin resistance. However, further research is crucial, especially for individuals with 'lean PCOS' who are not obese.
